FDA Peptide Tracker

SS-31 / Elamipretide: live FDA regulatory status

Mitochondrial cardiolipin binder · Approved (narrow)

The two signals

Plain-English verdict: amber.

Regulatory status: Approved (Barth) · off-label otherwise.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Education only

What happens next

Longevity use remains off-label — Ongoing

Regulatory timeline

• 2025-09 — FDA accelerated approval, Barth syndrome
• Ongoing — Energy / longevity use is off-label

SS-31 / Elamipretide: common questions

Is SS-31 (elamipretide) legal in 2026?

Partly, and the distinction is the whole answer. Elamipretide has a narrow FDA approval for Barth syndrome. Any longevity or performance use is off-label and is not what that approval covers.

Can I get SS-31 for longevity right now?

No. SS-31 is education-only at Peptós.LIFE. We do not offer approved drugs off-label for longevity claims.

Does the Barth syndrome approval mean SS-31 is proven for aging?

No. An approval is specific to the condition, population and evidence it was granted for. Extending it to healthy aging is exactly the leap our evidence grading exists to flag.

What happens next for SS-31?

Longevity use remains off-label. Nothing scheduled would change that.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.